NCT06648057 2026-03-18
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
CHA University
Recruiting
Clinical Trials
23 trialsNCT07142226 2026-03-18
Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC
CHA University
Recruiting
NCT07151118 2026-03-18
ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer
CHA University
Recruiting
NCT07466238 2026-03-12
HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
Peking University
Not yet recruiting
NCT02829918 2026-03-11
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT07454486 2026-03-06
TRACE-BTC
Aarhus University Hospital
Not yet recruiting
NCT06789848 2026-02-27
Ligufalimab and Cadonilimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT07437287 2026-02-27
CROCOBIL
UNICANCER
Phase 2/3 Not yet recruiting
NCT04907643 2026-02-20
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
Phase NA Recruiting
NCT07146646 2026-02-19
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT03785873 2026-02-13
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT07107750 2026-02-04
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Washington University School of Medicine
Phase 1 Not yet recruiting
NCT04005339 2026-01-26
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
Georgetown University
Phase 2 Active not recruiting
NCT05036486 2026-01-20
The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer
National Health Research Institutes, Taiwan
Active not recruiting
NCT05170438 2026-01-20
LenPac
National Health Research Institutes, Taiwan
Phase 2 Active not recruiting
NCT05254847 2026-01-20
Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC
Fudan University
Phase 2 Completed
NCT06548412 2026-01-20
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07235007 2026-01-13
BRAVE
Aichi Medical University
Phase NA Recruiting
NCT07337850 2026-01-13
FAPi-2
Tata Memorial Centre
Recruiting
NCT02917759 2026-01-09
Liver and Biliary Tumor Tissue Registry
Mayo Clinic
Terminated
NCT04896931 2026-01-07
New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a Permanent Platform Including All Kind of Biliary Tract Cancers (BTC)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Completed
NCT07319767 2026-01-06
Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant Tumors
Shanghai Zhongshan Hospital
Completed
NCT04203160 2025-12-31
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated